Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 23, 2021

Residual Cancer Burden Score May Predict a Patient’s Residual Risk After Neoadjuvant Chemotherapy

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Lancet Oncol 2021 Dec 10;[EPub Ahead of Print], C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, AS Hamy, M Laé, F Reyal, GS Sonke, TG Steenbruggen, M van Seijen, J Wesseling, M Martín, M Del Monte-Millán, S López-Tarruella, , JC Boughey, MP Goetz, T Hoskin, R Gould, V Valero, SB Edge, JE Abraham, JMS Bartlett, C Caldas, J Dunn, H Earl, L Hayward, L Hiller, E Provenzano, SJ Sammut, JS Thomas, D Cameron, A Graham, P Hall, L Mackintosh, F Fan, AK Godwin, K Schwensen, P Sharma, AM DeMichele, K Cole, L Pusztai, MO Kim, LJ van 't Veer, LJ Esserman, WF Symmans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading